SOTIO is a biotechnology company that applies unique and novel procedures to develop new medicines. The company is looking for talented, motivated, dynamic employees to join its international team ...
PPF has a vision to build a diversified biotech portfolio of innovative therapies for the treatment of cancer. SOTIO aims to become a diverse oncology specialty pharma company. We seek to add ...
Basel, Switzerland & Prague, Czech Republic – November 7, 2019 – NBE-Therapeutics AG and SOTIO a.s. today announced that SOTIO has elected a second target for the development of a next generation ...
Phase II Clinical Trials of DCVAC/PCa - besides Phase III VIABLE study we have initiated five Phase II clinical trials for patients with prostate cancer at various stages of the disease. Recently launched SP015 clinical trial evaluating combination of DCVAC/PCa and ONCOS-102, an immune-priming adenovirus, is currently enrolling patients in the Czech Republic.
Phase II Clinical Trials of DCVAC/OvCa - four Phase II clinical trials have been launched to assess the effect of addition of DCVAC platform (DCVAC/OvCa) to standard of care chemotherapy in patients with ovarian cancer at various stages of the disease. SOV01 and SOV06 clinical trials are currently enrolling patients with epithelial ovarian cancer.
Phase I/II Clinical Trial DCVAC/LuCa - SLU01 study was launched to assess the use of DCVAC platform (DCVAC/LuCa) combined with standard treatments in patients with advanced lung cancer. This clinical trial recruited patients at medical centers in the Czech Republic and Slovakia and is currently in the phase of final evaluation.